Nisa Investment Advisors
TRDA icon

Nisa Investment Advisors’s Entrada Therapeutics TRDA Stock Holding History

Nisa Investment Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9K Buy
2,972
+2,811
+1,746% +$27K ﹤0.01% 2182
2026
Q1 		$2.03K Hold
161
– – ﹤0.01% 2612
2025
Q4 		$1.66K Hold
161
– – ﹤0.01% 2636
2025
Q3 		$934 Buy
161
+28
+21% +$164 ﹤0.01% 2757
2025
Q2 		$894 Buy
133
+106
+393% +$853 ﹤0.01% 2759
2025
Q1 		$244 Sell
27
-100
-79% -$1.25K ﹤0.01% 2904
2024
Q4 		$2.2K Buy
127
+106
+505% +$1.92K ﹤0.01% 2457
2024
Q3 		$336 Sell
21
-37
-64% -$583 ﹤0.01% 2787
2024
Q2 		$827 Buy
58
+27
+87% +$384 ﹤0.01% 2562
2024
Q1 		$439 Buy
31
+21
+210% +$297 ﹤0.01% 2521
2023
Q4 		$151 Buy
+10
New +$148 ﹤0.01% 2586
2022
Q2 		– Sell
-700
Closed -$7K – 2509
2022
Q1 		$7K Buy
+700
New +$7.5K ﹤0.01% 2266

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Nisa Investment Advisors's TRDA Position: Q2 2026 in Review

Nisa Investment Advisors increased its Entrada Therapeutics (TRDA) stake by 1,746% in Q2 2026, buying an estimated $27K and bringing the position to 2,972 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2182.

Nisa Investment Advisors first reported a position in TRDA in Q1 2022 and has held it in 12 quarters since. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Nisa Investment Advisors held 2,972 shares of Entrada Therapeutics worth $21.9K as of Q2 2026.
  • Nisa Investment Advisors bought 2,811 Entrada Therapeutics shares in Q2 2026, an estimated $27K.
  • Entrada Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2182 holding.
  • Nisa Investment Advisors first reported a position in Entrada Therapeutics in Q1 2022 and has held it in 12 quarters since.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.